Thermo Fisher Scientific (NYSE:TMO) Reaches New 52-Week High – Time to Buy?

Thermo Fisher Scientific Inc. (NYSE:TMO) shares reached a new 52-week high on Thursday . The company traded as high as $629.54 and last traded at $629.2060, with a volume of 1346335 shares traded. The stock had previously closed at $621.83.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TMO. UBS Group raised their price objective on Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Wall Street Zen cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Stifel Nicolaus lifted their target price on Thermo Fisher Scientific from $583.00 to $700.00 and gave the company a “buy” rating in a report on Friday, January 9th. Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research report on Wednesday, January 7th. Finally, Leerink Partners increased their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $625.47.

Thermo Fisher Scientific Trading Up 0.6%

The stock has a 50 day moving average of $584.24 and a 200 day moving average of $521.63. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The firm has a market cap of $235.03 billion, a P/E ratio of 36.17, a PEG ratio of 3.99 and a beta of 0.91.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. During the same period in the previous year, the firm posted $5.28 earnings per share. The firm’s revenue for the quarter was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be issued a $0.43 dividend. The ex-dividend date is Monday, December 15th. This represents a $1.72 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.94%.

Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase program on Thursday, November 6th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, COO Michel Lagarde sold 22,046 shares of the company’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $563.56, for a total transaction of $12,424,243.76. Following the completion of the transaction, the chief operating officer owned 84,117 shares in the company, valued at $47,404,976.52. This represents a 20.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Frederick M. Lowery sold 6,912 shares of the firm’s stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $581.94, for a total value of $4,022,369.28. Following the completion of the sale, the executive vice president directly owned 14,367 shares of the company’s stock, valued at $8,360,731.98. The trade was a 32.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 149,271 shares of company stock valued at $86,507,282 over the last ninety days. Corporate insiders own 0.33% of the company’s stock.

Hedge Funds Weigh In On Thermo Fisher Scientific

A number of institutional investors have recently bought and sold shares of the stock. JPL Wealth Management LLC bought a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $28,000. Highline Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares in the last quarter. Beacon Financial Strategies CORP bought a new position in shares of Thermo Fisher Scientific in the 4th quarter worth about $29,000. Olistico Wealth LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Capital A Wealth Management LLC grew its holdings in Thermo Fisher Scientific by 825.0% in the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after purchasing an additional 66 shares during the period. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.